NASDAQ:RVMD

Revolution Medicines Competitors

$42.67
-2.35 (-5.22 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$42.52
Now: $42.67
$45.64
50-Day Range
$41.28
MA: $45.83
$49.54
52-Week Range
$20.53
Now: $42.67
$56.18
Volume645,521 shs
Average Volume573,372 shs
Market Capitalization$3.13 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Revolution Medicines (NASDAQ:RVMD) Vs. QGEN, RGEN, NBIX, CRSP, XLRN, and FATE

Should you be buying RVMD stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Revolution Medicines, including QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Acceleron Pharma (XLRN), and Fate Therapeutics (FATE).

QIAGEN (NYSE:QGEN) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Institutional and Insider Ownership

43.6% of QIAGEN shares are owned by institutional investors. Comparatively, 85.8% of Revolution Medicines shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and price targets for QIAGEN and Revolution Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QIAGEN05902.64
Revolution Medicines00203.00

QIAGEN presently has a consensus target price of $60.76, indicating a potential upside of 18.46%. Revolution Medicines has a consensus target price of $51.00, indicating a potential upside of 19.52%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Revolution Medicines is more favorable than QIAGEN.

Earnings and Valuation

This table compares QIAGEN and Revolution Medicines' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QIAGEN$1.53 billion7.66$-41,460,000.00$1.4335.87
Revolution Medicines$50.04 million62.57$-47,660,000.00N/AN/A

QIAGEN has higher revenue and earnings than Revolution Medicines.

Profitability

This table compares QIAGEN and Revolution Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QIAGEN11.18%17.51%8.44%
Revolution Medicines-191.17%-32.25%-20.55%

Summary

QIAGEN beats Revolution Medicines on 7 of the 11 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Revolution Medicines and Repligen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines00203.00
Repligen00503.00

Revolution Medicines currently has a consensus target price of $51.00, suggesting a potential upside of 19.52%. Repligen has a consensus target price of $204.75, suggesting a potential downside of 0.66%. Given Revolution Medicines' higher possible upside, equities analysts plainly believe Revolution Medicines is more favorable than Repligen.

Insider & Institutional Ownership

85.8% of Revolution Medicines shares are held by institutional investors. Comparatively, 84.3% of Repligen shares are held by institutional investors. 1.7% of Repligen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Revolution Medicines and Repligen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million62.57$-47,660,000.00N/AN/A
Repligen$270.24 million41.77$21.41 million$1.07192.62

Repligen has higher revenue and earnings than Revolution Medicines.

Profitability

This table compares Revolution Medicines and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
Repligen13.40%6.58%5.00%

Summary

Repligen beats Revolution Medicines on 7 of the 10 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Neurocrine Biosciences (NASDAQ:NBIX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Revolution Medicines and Neurocrine Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
Neurocrine Biosciences8.96%18.18%9.50%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Revolution Medicines and Neurocrine Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines00203.00
Neurocrine Biosciences081202.60

Revolution Medicines presently has a consensus price target of $51.00, indicating a potential upside of 19.52%. Neurocrine Biosciences has a consensus price target of $129.2222, indicating a potential upside of 38.43%. Given Neurocrine Biosciences' higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Revolution Medicines.

Insider & Institutional Ownership

85.8% of Revolution Medicines shares are owned by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Revolution Medicines and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million62.57$-47,660,000.00N/AN/A
Neurocrine Biosciences$788.10 million11.13$37.01 million$0.39239.36

Neurocrine Biosciences has higher revenue and earnings than Revolution Medicines.

Summary

Neurocrine Biosciences beats Revolution Medicines on 9 of the 11 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Revolution Medicines and CRISPR Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines00203.00
CRISPR Therapeutics241202.56

Revolution Medicines presently has a consensus price target of $51.00, suggesting a potential upside of 19.52%. CRISPR Therapeutics has a consensus price target of $158.80, suggesting a potential upside of 37.20%. Given CRISPR Therapeutics' higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Revolution Medicines.

Valuation & Earnings

This table compares Revolution Medicines and CRISPR Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million62.57$-47,660,000.00N/AN/A
CRISPR Therapeutics$289.59 million30.15$66.86 million$1.1798.92

CRISPR Therapeutics has higher revenue and earnings than Revolution Medicines.

Profitability

This table compares Revolution Medicines and CRISPR Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
CRISPR Therapeutics-273.10%-20.72%-18.35%

Institutional and Insider Ownership

85.8% of Revolution Medicines shares are owned by institutional investors. Comparatively, 66.4% of CRISPR Therapeutics shares are owned by institutional investors. 17.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

CRISPR Therapeutics beats Revolution Medicines on 7 of the 11 factors compared between the two stocks.

Acceleron Pharma (NASDAQ:XLRN) and Revolution Medicines (NASDAQ:RVMD) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Institutional and Insider Ownership

79.8% of Acceleron Pharma shares are held by institutional investors. Comparatively, 85.8% of Revolution Medicines shares are held by institutional investors. 2.5% of Acceleron Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Acceleron Pharma and Revolution Medicines' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acceleron Pharma$73.99 million103.81$-124,860,000.00($2.38)-53.30
Revolution Medicines$50.04 million62.57$-47,660,000.00N/AN/A

Revolution Medicines has lower revenue, but higher earnings than Acceleron Pharma.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Acceleron Pharma and Revolution Medicines, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acceleron Pharma031012.86
Revolution Medicines00203.00

Acceleron Pharma presently has a consensus price target of $148.2143, indicating a potential upside of 16.84%. Revolution Medicines has a consensus price target of $51.00, indicating a potential upside of 19.52%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Acceleron Pharma.

Profitability

This table compares Acceleron Pharma and Revolution Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acceleron Pharma-157.84%-31.62%-28.11%
Revolution Medicines-191.17%-32.25%-20.55%

Summary

Acceleron Pharma beats Revolution Medicines on 7 of the 12 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Fate Therapeutics (NASDAQ:FATE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares Revolution Medicines and Fate Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
Fate Therapeutics-810.13%-35.51%-25.40%

Insider and Institutional Ownership

85.8% of Revolution Medicines shares are held by institutional investors. Comparatively, 99.7% of Fate Therapeutics shares are held by institutional investors. 21.4% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Revolution Medicines and Fate Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million62.57$-47,660,000.00N/AN/A
Fate Therapeutics$10.68 million684.84$-98,150,000.00($1.44)-54.16

Revolution Medicines has higher revenue and earnings than Fate Therapeutics.

Analyst Ratings

This is a breakdown of current ratings and price targets for Revolution Medicines and Fate Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines00203.00
Fate Therapeutics04902.69

Revolution Medicines currently has a consensus target price of $51.00, indicating a potential upside of 19.52%. Fate Therapeutics has a consensus target price of $108.3125, indicating a potential upside of 38.88%. Given Fate Therapeutics' higher possible upside, analysts plainly believe Fate Therapeutics is more favorable than Revolution Medicines.

Summary

Revolution Medicines beats Fate Therapeutics on 6 of the 11 factors compared between the two stocks.


Revolution Medicines Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
QIAGEN logo
QGEN
QIAGEN
1.5$51.29-0.2%$11.69 billion$1.53 billion63.32Analyst Report
Repligen logo
RGEN
Repligen
1.5$206.10-0.9%$11.29 billion$270.24 million251.34News Coverage
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.35-0.7%$8.77 billion$788.10 million100.38Analyst Downgrade
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$115.74-4.0%$8.73 billion$289.59 million-35.50
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$126.85-1.9%$7.68 billion$73.99 million-48.98
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$77.99-1.3%$7.31 billion$10.68 million-42.39Analyst Revision
Twist Bioscience logo
TWST
Twist Bioscience
1.2$132.23-0.1%$6.43 billion$90.10 million-35.26Analyst Upgrade
Insider Selling
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$52.26-1.4%$6.32 billion$26.68 million-23.65Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.77-1.3%$6.13 billion$195.99 million267.31
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$40.42-4.0%$5.63 billion$85.07 million-42.55Insider Selling
News Coverage
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$109.07-1.1%$5.58 billionN/A-47.01
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$43.13-3.9%$5.52 billion$8.09 million-18.28Analyst Upgrade
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.00-0.2%$4.64 billion$503.70 million32.96
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.82-2.5%$4.62 billionN/A-15.41News Coverage
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.19-3.7%$4.44 billionN/A-15.72Unusual Options Activity
News Coverage
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$70.23-6.5%$4.39 billion$20,000.00-5.00News Coverage
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$68.95-3.5%$3.38 billionN/A-39.63
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$70.33-0.1%$3.14 billion$125.57 million-41.13
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$33.63-5.1%$3.04 billionN/A0.00
Vericel logo
VCEL
Vericel
1.3$57.77-3.5%$2.66 billion$117.85 million-5,777,000.00News Coverage
Editas Medicine logo
EDIT
Editas Medicine
1.6$39.46-3.3%$2.66 billion$20.53 million-22.68
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.51-3.1%$2.11 billion$31.43 million-5.14News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$23.88-1.0%$1.94 billionN/A-11.16
bluebird bio logo
BLUE
bluebird bio
1.8$28.16-2.5%$1.89 billion$44.67 million-2.56
NantKwest logo
NK
NantKwest
1.1$16.87-10.8%$1.84 billion$40,000.00-23.76News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.21-1.9%$1.81 billion$48.83 million-13.43
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.02-2.1%$1.58 billion$102.43 million-18.37Analyst Upgrade
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$69.29-6.8%$1.54 billionN/A-46.82
Immunovant logo
IMVT
Immunovant
1.8$15.68-1.4%$1.54 billionN/A-12.16Unusual Options Activity
AlloVir logo
ALVR
AlloVir
1.4$23.21-5.2%$1.51 billionN/A0.00
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$33.44-4.6%$1.50 billionN/A0.00News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.17-0.0%$1.49 billion$35.23 million-14.18News Coverage
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.66-3.2%$1.41 billionN/A0.00Insider Selling
High Trading Volume
Replimune Group logo
REPL
Replimune Group
1.5$30.07-1.9%$1.40 billionN/A-16.99
Alector logo
ALEC
Alector
1.3$17.37-13.0%$1.38 billion$21.22 million-7.79Insider Selling
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$6.96-0.7%$1.31 billionN/A-4.70
Translate Bio logo
TBIO
Translate Bio
1.6$17.26-2.1%$1.30 billion$7.80 million-16.13
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.77-3.1%$1.15 billionN/A-2.98
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.90-0.9%$1.15 billion$100.56 million0.00
Mesoblast logo
MESO
Mesoblast
1.4$8.51-0.6%$1.10 billion$32.16 million-9.67Analyst Upgrade
News Coverage
Curis logo
CRIS
Curis
1.3$11.50-2.9%$1.05 billion$10 million-14.02
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.22-2.7%$1.04 billionN/A0.00
Scholar Rock logo
SRRK
Scholar Rock
1.5$29.94-6.2%$1.03 billion$20.49 million-12.42
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.95-1.1%$1.02 billion$356.07 million6.84
Cortexyme logo
CRTX
Cortexyme
1.3$33.59-6.9%$992.65 millionN/A-14.00Gap Up
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.10-5.8%$922.43 million$42.74 million-223.33
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$24.63-0.9%$890.08 millionN/A-4.07
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.08-6.9%$887.99 million$250,000.00-7.15News Coverage
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.83-0.7%$883.45 million$69.89 million-4.49
Passage Bio logo
PASG
Passage Bio
1.8$16.34-4.4%$879.60 millionN/A0.00News Coverage
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.